Side-by-side comparison of AI visibility scores, market position, and capabilities
Austin MN branded food (NYSE: HRL) ~$11.9B FY2024 revenue; SPAM/Skippy/Planters/Jennie-O portfolio, 250-position restructuring 2025, Planters $3.35B integration challenge competing with Tyson and Conagra.
Hormel Foods Corporation is an Austin, Minnesota-based multinational food company — publicly traded on the New York Stock Exchange (NYSE: HRL) as an S&P 500 Consumer Staples component — producing, marketing, and distributing branded consumer food products across refrigerated, shelf-stable, and deli categories under the Hormel, SPAM, Jennie-O, Skippy, Planters, Columbus Craft Meats, Applegate, Justin's, Natural Choice, and Wholly brands through approximately 20,000 employees serving customers across 80+ countries. In fiscal year 2024 (ending October 2024), Hormel reported revenue of approximately $11.9 billion, with performance reflecting challenges in the turkey market (Jennie-O facing supply and competitive dynamics), commodity cost management, and ongoing integration of the Planters snack nuts business (acquired from Kraft Heinz in 2021 for $3.35 billion). Hormel announced a comprehensive corporate restructuring in 2025 — including a voluntary early retirement program and the elimination of approximately 250 corporate and sales positions — targeting $20-25 million in restructuring charges as the company streamlines operations to improve efficiency and align resources with strategic priorities following the Planters acquisition integration challenge. CEO Jim Snee leads Hormel's "Transform and Modernize" strategy focusing on operational efficiency, brand investment, and portfolio optimization. The Planters acquisition (peanuts, cashews, mixed nuts, peanut butter, Cheez Balls) gave Hormel a leading position in the $8B+ US nut snack market but has required margin improvement work.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.